1. Home
  2. CRBP vs DPRO Comparison

CRBP vs DPRO Comparison

Compare CRBP & DPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CRBP

Corbus Pharmaceuticals Holdings Inc.

N/A

Current Price

$11.31

Market Cap

190.3M

Sector

Health Care

ML Signal

N/A

Logo Draganfly Inc.

DPRO

Draganfly Inc.

N/A

Current Price

$5.41

Market Cap

188.8M

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
CRBP
DPRO
Founded
2009
1998
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Aerospace
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
190.3M
188.8M
IPO Year
2014
2019

Fundamental Metrics

Financial Performance
Metric
CRBP
DPRO
Price
$11.31
$5.41
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
3
Target Price
$45.50
$15.00
AVG Volume (30 Days)
516.3K
1.2M
Earning Date
05-08-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,822,272.00
N/A
Revenue This Year
N/A
$158.69
Revenue Next Year
$116.00
$131.85
P/E Ratio
N/A
N/A
Revenue Growth
97.62
N/A
52 Week Low
$7.12
$3.78
52 Week High
$20.56
$14.37

Technical Indicators

Market Signals
Indicator
CRBP
DPRO
Relative Strength Index (RSI) 66.21 66.16
Support Level $7.62 $4.96
Resistance Level $11.64 $5.69
Average True Range (ATR) 0.60 0.27
MACD 0.07 0.10
Stochastic Oscillator 83.08 81.98

Price Performance

Historical Comparison
CRBP
DPRO

About CRBP Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

About DPRO Draganfly Inc.

Draganfly Inc is a Canada based company. It is engaged in the provision of engineering services and the manufacture of commercial unmanned vehicle systems and software. The company operates in Canada, the United States, and Internationally. The two segments are Drones, and Corporate. The Drones segment derives its revenue from products and services related to the sale of unmanned aerial vehicles (UAV). The Corporate segment includes all costs not directly associated with the Drone and Vital segments. It generates majority of its revenue from Drones segment.

Share on Social Networks: